Education
About Us
Working with TipRanks
Follow Us
Hls Therapeutics (TSE:HLS)
:HLS
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.18Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 3.56%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in Vascepa sales and a significant reduction in operating expenses and debt, positioning the company for a stronger financial future. However, challenges such as the decline in U.S. Clozaril sales and lowered revenue guidance tempered the overall outlook.Company Guidance
During the Q3 2024 earnings call for HLS Therapeutics, the company provided guidance reflecting both achievements and future expectations. HLS reported third-quarter revenue of $14.1 million, with adjusted EBITDA of $4.1 million and cash from operations at $1.5 million. A significant highlight was the robust performance of Vascepa in Canada, with net sales increasing by 28% year-over-year, or 30% in constant currency. The company also reduced Q3 operating expenses by 15% compared to the previous year, excluding the cost of goods, and made a substantial debt repayment, lowering net debt to $52.4 million. Full-year guidance for 2024 was adjusted, with revenue now anticipated to be between $56.5 million and $57.2 million, and the adjusted EBITDA range raised to $16 million to $16.7 million. Looking ahead to 2025, HLS expects revenue growth in the high single-digit percentage range and consolidated adjusted EBITDA growth in the mid-20s percentage range.Strong Vascepa Sales Growth
Vascepa's net sales increased 28% year-over-year, 30% in constant currency, and were up 13% over the second quarter, with unit demand growing 45% in Q3. Prescriber growth was consistent at 66%.
Reduction in Operating Expenses
Operating expenses were reduced by 15% in Q3 compared to the prior year, with a significant debt repayment strengthening the company's balance sheet.
Positive Leadership Announcements
John Hanna was appointed as the permanent Chief Financial Officer and Brian Walsh was promoted to Chief Commercial Officer, contributing to significant changes in operating performance.
Canadian Market Success
Net sales in Canada grew 9% in Q3 over the prior year, with Vascepa contributing significantly to this growth.
Debt Reduction Achievements
Debt was reduced by more than $18 million, putting the company in a much stronger financial position entering 2025.
Promising Future Sales Model
Transition of primary care sales activities in-house from Pfizer is expected to save approximately $4 million annually, maintaining a high level of coverage with existing prescribers.
---
TSE:HLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:HLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | C$4.49 | C$4.60 | +2.45% |
Mar 13, 2025 | C$4.01 | C$3.96 | -1.25% |
Nov 07, 2024 | C$3.40 | C$3.70 | +8.82% |
Aug 08, 2024 | C$3.05 | C$3.12 | +2.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Hls Therapeutics (TSE:HLS) report earnings?
Hls Therapeutics (TSE:HLS) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Hls Therapeutics (TSE:HLS) earnings time?
Hls Therapeutics (TSE:HLS) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:HLS EPS forecast?
TSE:HLS EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.
---